

# Japan Brain Bank Network

Specially Appointed Professor,  
Brain Bank for Neurodevelopmental, Neurological and  
Psychiatric Disorders,  
United Graduate School of Child Development,  
Osaka University

Specially Appointed Researcher  
The Brain Bank for Aging Research  
Tokyo Metropolitan Geriatric Hospital and Institute of  
Gerontology (Cross Appointment)

**Shigeo Murayama M.D. Ph.D.**

I will talk about Japan Brain Bank Network. I am working with two brain bank system in Japan.

## My Background

- I am a Zen master of Soto school of Zen (曹洞宗).
- I have been educated that those who have eaten food offered to Buddha (仏飯) should dedicate their life to all living creatures on earth (衆生).
- To establish all Japan Brain Bank Network is my life work, which I interpret to be Bodhisattva line (菩薩行).
- I will go anywhere to fulfill brain donors' will or guide doctors who want to contribute to brain banking.

My background is a buddhist priest and feels sincere respect for people in India.

## COI

Honorable Member: the Japanese Societies of Neurology,  
Neuropathology and Dementia Research  
Associate Editor, Journal of Neuropathology and  
Experimental Neurology  
Visiting Professor: Tokushima, Hiroshima, Tokyo Medical,  
Doshisha and Osaka City Universities;  
Neuropathology Consultant: National Center for Global  
Medicine, National Hospital Organization, Tokyo,  
Shimoshizu, Shizuoka Epilepsy and Neurology, West  
Hiroshima and Okinawa Hospitals; Kagawa University;  
Kameda, Yokohama Rosai, Toranomom, NTT East Kanto  
and Chikamori Hospitals

My COI is as follows. I will go anywhere to fulfill the will of brain donation.


# The Brain Bank for Aging Research (BBAR)



Tokyo Metropolitan Geriatric Hospital & Institute of Gerontology



Brain Bank is a movement conducted by patients, doctors and researchers, to conquer intractable neuro- psychiatric disorders.  
Kazutomo Imahori



The Brain Bank for Aging Research is defined as activity of TMGHIG funded by Tokyo Metropolitan government in collaboration of all members of our institute.

## The Brain Bank for Aging Research (BBAR)



TMGHIG

Resources consisting of consecutive autopsy cases from a general geriatric hospital & all Japan depository of rare neurological and developmental disorders (<http://www.mci.gr.jp/BrainBank>)  
In House Cohort Resource




1. Paraffin blocks and glass slides (1972.5–)  
for Clinical, Radiological and Pathological Research 7418
- >2. Frozen neocortex and body tissues (1995.1–)  
for Molecular Research: 2,415
- >3. Frozen half brains (2001.7– )  
for Neuroscience Research: 1,102

All Japan Neurological and Developmental Depository

In collaboration with Brain Bank for Neurodevelopmental,  
Neurological and Psychiatric Disorders (BBNNPD)

The Brain Bank for Aging Research has been accumulating paraffin blocks of brain and body tissues since 1972, frozen small pieces of brain and body tissues since 1995 and frozen half brains, spinal cords and peripheral autonomic nervous tissues since 2001. We are also responsible for all Japan depository of rare intractable neurological disorders.



Japanese Brain Bank Network, Kansai Base was established in 2020 in collaboration with Osaka University, National Hospital Organization (NHO) and Osaka Prefectural Hospital Organization.

# Brain Donation Program

Dr. Yasuo Toyokura  
80y.o. +  
Em. Pro.  
Univ. Tokyo  
Em. Direc.  
TMGHIG  
The first  
brain donor  
of BBAR



Death Note:  
"Please use our body to  
conquer diseases that will kill  
me (and you cannot cure)."

Donor Card

**高齢者ブレインバンク  
献脳ドナー登録カード**


本カード所持者は高齢者ブレインバンクへの献脳ドナー登録者です。

献脳ドナー登録者の死亡時に、ご遺族が献脳に同意いただける場合には、事務局へ電話連絡をお願いします。

**TEL: 03-3964-3241 内線3046 (平日9時~17時)**


**TEL: 090-2549-8267 (上記以外の時間帯)**

高齢者ブレインバンク事務局  
〒173-0015 東京都板橋区栄町35-2 東京都健康長寿医療センター内




Dr. Toyokura, the Late Emeritus Professor the University of Tokyo and Emeritus President of TMGHIG was the founder of our brain donation program.

"Please use my body to cure the incurable diseases that will kill me." He suffered from cardiomyopathy with a mutation of myosin light chain and died at age of 80 years.



BBNPD and BBAR form the core of the Japanese Brain Bank Network for Neuroscience Research, funded by MEXT, collaborating with the National Center of Neurology and Psychiatry (NCNP), Mihara Memorial Hospital and Fukushima Hospital. Dr. Yasuo Ihara, a preregistered brain donor for BBAR and Emeritus Professor, the University of Tokyo, has been contributing to this frame from the beginning.





Japan Brain Bank Net (JBBN) is funded by AMED, first in 2016 and renewed in 2021. Dr. Masaki Takao, the director of NCNP Brain Bank is PI. BBAR takes responsibility for aging and dementia and BBNNPD for suicide and pediatric registry. The establishment of JBBN was Emeritus Professor Kanazawa's dream, who was registered to BBAR on January 21, 2016, just before the start of JBBN.

### The Brain Bank Network

Institute	Clinician/ Pathologist	2012	2013	2014	2015	2016	2017	2018	2019	2020	
BBAR	Iwata, A./ Saito, Y.	63	39	39	45	64	52	39	36	36	
NCNP	Takahashi, Y./ Takao, M.	10	10	11	9	13	18	24	14	22	
Mihara	Mihara, B./ Takao, M.	29	26	15	19	23	16	19	33	18	
Fukushima	Kaneda, D./ Hashizume, Y.	36	31	27	25	25	21	25	33	40	
Osaka Univ.	Mochizuki, H./ Murayama, S.					3	4	6	6	5	
NHO Toneyama	Inoue, K.							18	16	12	
Tokushima, U.	Izumi, Y./ Tsuneyama, K.	1	3	5	10	4	12	4	5	3	
Univ. Tokyo	Kubota, A./ Ikemura, M.	28	23	22	25	26	15	17	18	21	
NCGM	Arai, T./ Igari, T.	23	16	17	27	17	17	9	9	7	
NHO Tokyo	Komiya, T./	5	5	2	4	3	0	1	1	1	
NHO Shizuoka	Obi, T.	1	2	2	4	6	6	4	2	2	
Yokohama Rosai	Imafuku, I/ Kakuta, Y.	1	6	6	8	8	4	4	4	2	
Kameda	Ando, T/ Takeuchi, R.	12	10	6	9	12	10(2)	10(2)	10(2)	5(4)	
Kitazato Y.	Nishiyama, K./ Ichinohe, M.	7	9	5	4	2	6	6	1	1	
Mita IUHW	Iwata, N./ Aida, S.	2	3	2	0	2	1	1	2	0	
Kagawa U.	Kamada, M./ Ueno, M.	2	4	3	1	1	1	2	1	0	
Toranomon	Uesaka, Y./ Ito, S.		3	1	2	2	3	1	8	2	
Teikyo, U.	Sonoo, M./ Uozaki, H.	3	2	2	0	4	0	4	2	0	
Tokyo Teishin	Shiio, Y./ Kishida, Y.	5	2	2	3	5	3	0	3	3(2)	
Tokyo Medical U.	Aizawa, H./ Kuroda, M.	1	0	0	1	0	1				
NHO E. Hiroshima	Watanabe, C./Tachiyama, Y					3	4	4	2	4	0
Osaka City Univ.	Ito, Y./ Osawa, M.			1	1	1	1	0		1	0
NHO Sagamihara	Hasegawa, I./ Yagishita, S.					8	10	18	18	17	8
NHO Okinawa	Suwazono, S./ Atami, E.					1	2	2	4	2	0
Open Resource		140	109	100	110	156	155	168	171	163	
Inst. Collection (MEXT, AMED)		79	85	84	105	74	69	50	67	35	

We tried to increase open brain resource for neuroscience research, in collaboration with clinicians and pathologists.

Brain Bank Registrants BBAR (Aug. 2021) : (Preregistrants: 203)																	
No.	Age	Gen.	Dix	Con.	Place of death/ auto.	No.	年齢	性別	Dix	同意	死亡場所・剖検施設	No.	年齢	性別	Dix	同意	死亡場所・剖検施設
1	80	M	Heart	S	TMGHIG	28	83	F	PSP	F	Body transfer	55	44	M	SPG11	F	Body transfer
2	83	M	FAD	F	Body transfer	29	90	F	AD	S	Body transfer	56	78	F	AGD	F	Body transfer
3	79	F	FAD	F	Brain transfer	30	87	F	AD	F	Body transfer	57	85	M	CJD MV1 (renal Ca)	S	Body transfer
4	69	F	CBD-PNFA/TDP-43 type A	F	Body transfer	31	95	M	AGD	S	Body transfer	58	85	M	(renal Ca)	S	Body transfer
5	86	F	AD	F	Brain transfer	32	85	M	AGD	F	Body transfer	59	61	M	ALS (Lung Ca)	S	Brain transfer
6	91	M	AD/CAA/DG/HS-TDP-43	S	Body transfer	33	80	F	ALS	F	Body transfer	60	86	M	(Lung Ca)	F	Body transfer
7	84	F	PSP (Colon Ca)	S	Body Transfer	34	80	M	SMA	F	Body transfer	61	82	F	(CVD)	F	TMGHIG
8	89	F	(Colon Ca)	S	TMGHIG	35	70	F	PSP	F	Body transfer	62	85	F	PSP	F	Body transfer
9	84	M	CVD	F	TMGHIG	36	68	M	CBD	F	Body transfer	63	92	M	AD	F	Body transfer
10	86	M	AD	F	TMGHIG	37	84	M	ALS	S	Body transfer	64	61	F	fCJD	F	Body transfer
11	88	F	DLB	F	Body transfer	38	69	M	PSP	S	Brain transfer	65	85	F	CJD/PD	F	Body transfer
12	93	F	PD	S	TMGHIG	39	86	M	PDD	F	Body transfer	66	82	F	PSP	F	Body transfer
13	99	F	DLB	F	Body transfer	40	93	M	PSP	F	Brain transfer	67	49	F	NMO	F	Body transfer
14	73	M	(肺癌)	F	Body transfer	41	87	F	Early AD	S	Body transfer	68	82	F	PSP	F	Body transfer
15	111	F	NFTD	F	Body transfer	42	77	F	AD	F	Body transfer	69	72	M	AD	F	Body transfer
16	90	F	AD	F	Body transfer	43	86	M	DLB/AD	F	Body transfer	70	41	F	SCA1	F	Body transfer
17	97	M	NFTD/PSP/LBD/DG	F	Body transfer	44	80	M	AD/AGD	F	Body transfer	71	83	M	AD	F	Body transfer
18	72	M	CVD	F	Body transfer	45	83	F	PSP	F	Body transfer	72	92	M	AD	F	Body transfer
19	61	M	Encephalit.	F	Body transfer	46	68	M	PSP	F	Body transfer	73	91	F	AD	F	TMGHIG
20	79	M	CJD	F	Body transfer	47	78	M	PSP	F	Body transfer	74	63	F	Tauopathy	F	Body transfer
21	83	M	Malignant ly.	F	Body transfer	48	102	F	(Influ.)	F	Body transfer	75	85	M	SCA6	S	Body transfer
22	95	F	iNPH	F	Body transfer	49	69	M	CVD	F	Brain trasfer	76	82	M	AD	S	Body transfer
23	80	F	ALS	F	TMGHIG	50	83	F	AD/DLB	F	Body transfer	77	57	M	CJD	F	Body transfer
24	78	F	PSP	F	Body transfer	51	63	M	Cereb. Con.	F	Body transfer	78	86	M	Y-10227 (pending)	F	Body transfer
25	74	M	LBD	F	Body transfer	52	86	M	FTLD-TDP typeC	F	Body transfer	79	65	F	Y-10231 (pending)	F	Body transfer
26	79	M	AD	F	Body transfer	53	89	F	CJD	F	Body transfer						
27	91	F	AD	F	Body transfer	54	94	M	eAD/AGD	F	Body transfer						

Brain Bank Registrants in BBAR reached 79 among 203 preregistrants.

## 2020 Collaboration

[www.mci.gr.jp/BrainBank/](http://www.mci.gr.jp/BrainBank/)

PI	Institute	Research theme
1 Ikeuchi, K.	NIBR	apoE4 and aging brain
2 Kuwano, R.	NIBR	miRNA editing in Alzheimer brain
3 Toda, T.	Kobe Univ.	Genomic pathology of neurological disease
4 Nishimura, M.	Mol. Neurosci. Shiga Med. Univ.	Novel protein in human aging
5 Hasegawa, M.	Tokyo Metro. Inst. Med. Sci.	CSF early biomarker of AD
6 Ono, M.	Pharm. Shiga Med. Univ.	Estrogen receptor in AD
7 Hisanaga, S.	Tokyo Metro. Univ.	Tau phosphorylation in tauopathy
8 Takahashi, Y.	Neurol. NCNP	Immunocytochemistry of ALS
9 Yamanaka, K.	Enviro. Res. Nagoya Univ.	Novel biomarker in neurodegeneration
10 Ito, M.	TMGHIG	SIRNA in argyrophilic grain disease
11 Okamura, N.	Tohoku Pharm. Univ.	Pet ligand for tau and alpha- synuclein
12 Miyasaka, T.	Life Sci. Doshisha Univ.	Imaging mass spectroscopy of human brain
13 Tanaka, M.	Riken	DISC1 and neurodegeneration
14 Tsuji, S.	Neurol. UT	Genomic screening in neurodegeneration
15 Ishikawa, K.	Neurol. TMDU	Genomic screening of ACA
16 Iwata, A.	Neurol. UT	Epigenetics of ALS
17 Tokumaru, A.	Radiol. TMGHIG	White matter change in MRI
18 Hattori, N.	Neurol. Junten. Univ.	Genomic screening of PD
19 Kwak, S.	Neurol. UT	RNA editing in ALS
20 Kubo, S.	Neurol. Junten. Univ.	Back ground pathology of early LBD
21 Okazawa, H.	Neuropath. TMDU	Proteomic analysis of neurodegeneration.
22 Kokubo, Y.	Mie Univ.	ALS/PDC Kii
23 Higuchi, M.	NIRS	alpha- synuclein ligand
24 Honma, N.	Patho. Toho Univ.	Estrogen receptor in AD
25 Hashimoto, Y.	Fukushima Med. Univ.	Glycosylation in AD
26 Sengoku, R.	Neurol. TMGHIG	Pathology of olfactory plate
27 Hashimoto, K.	Psy. Res. Cntr. Chiba Univ.	Lipid metabolism in PD
28 Saito, Y.	Life Sci. Doshisha Univ.	anti- oxidant DJ1 in LBD
29 Kato, T.	Riken	Neuropathology of depression
30 Nagata, N.	Animal Radiol. UT	L-PGDS in NPH
31 Kabuta, T.	NCNP	Chaperone- mediated autophagy
32 Sato, N.	NCGG	DM and demntia
33 Ri, M.	Juntendo Univ.	CHCHD2 gene in neurodegeneration
34 Ishii, K.	Pet Center TMGHIG	Neuropathology of tau imaging
35 Imaizumi, K.	Hiroshima Univ.	ER stress
36 Nagai, Y.	Osaka Univ.	exome analysis of in vivo proteostasis
37 Araki, I.	NCNP	BACE1 and synapse degeneration in AD
38 Yamagoshi, T.	NCGG	Salivary gland in aging
39 Kameyama, A.	AIST	Glycomics in aging
40 Ishigami, A.	TMGHIG	Citrullinated protein as an early biomarker of AD
41 Suhara, T.	NIRS	Dynamic pathology of amyloid- negative dementia
42 Ishiura, H.	Neurol. UT	High grade genome study of neurodegeneration

BBAR provided its resource to 42 laboratories in 2020.

## 2020 publication

- [1] Hamaguchi T, Sakai K, Kobayashi A, Kitamoto T, Ae R, Nakamura Y, Sanjo N, Arai K, Koide M, Katada F, Harada M, Murai H, Murayama S, Tsukamoto T, Mizusawa H, Yamada M: Characterization of Sporadic Creutzfeldt-Jakob Disease and History of Neurosurgery to Identify Potential Iatrogenic Cases. *Emerg Infect Dis* 2020, 26:1140-6.
- [2] Hamaguchi T, Sanjo N, Ae R, Nakamura Y, Sakai K, Takao M, Murayama S, Iwasaki Y, Satoh K, Murai H, Harada M, Tsukamoto T, Mizusawa H, Yamada M: MM2-type sporadic Creutzfeldt-Jakob disease: new diagnostic criteria for MM2-cortical type. *J Neurol Neurosurg Psychiatry* 2020.
- [3] Hata S, Hu A, Piao Y, Nakaya T, Taru H, Morishima-Kawashima M, Murayama S, Nishimura M, Suzuki T: Enhanced amyloid-beta generation by gamma-secretase complex in DRM microdomains with reduced cholesterol levels. *Hum Mol Genet* 2020, 29:382-93.
- [4] Hideshima M, Beck G, Yamadera M, Motoyama Y, Ikenaka K, Kakuda K, Tsuda H, Nagano S, Fujimura H, Morii E, Murayama S, Mochizuki H: A clinicopathological study of ALS with L126S mutation in the SOD1 gene presenting with isolated inferior olivary hypertrophy. *Neuropathology* 2020, 40:191-5.
- [5] Imai M, Tanaka M, Sakata M, Wagatsuma K, Tago T, Toyohara J, Sengoku R, Nishina Y, Kanemaru K, Ishibashi K, Murayama S, Ishii K: Metabolic Network Topology of Alzheimer's Disease and Dementia with Lewy Bodies Generated Using Fluorodeoxyglucose Positron Emission Tomography. *J Alzheimers Dis* 2020, 73:197-207.
- [6] Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S, Matoba N, Low SK, Okada Y, Terao C, Amariuta T, Gazal S, Kochi Y, Horikoshi M, Suzuki K, Ito K, Koyama S, Ozaki K, Niida S, Sakata Y, Sakata Y, Kohno T, Shiraiishi K, Momozawa Y, Hirata M, Matsuda K, Ikeda M, Iwata N, Ikegawa S, Kou I, Tanaka T, Nakagawa H, Suzuki A, Hirota T, Tamari M, Chayama K, Miki D, Mori M, Nagayama S, Daigo Y, Miki Y, Katagiri T, Ogawa O, Obara W, Ito H, Yoshida T, Imoto I, Takahashi T, Tanikawa C, Suzuki T, Sinozaki N, Minami S, Yamaguchi H, Asai S, Takahashi Y, Yamaji K, Takahashi K, Fujioka T, Takata R, Yanai H, Masumoto A, Koretsune Y, Kutsumi H, Higashiyama M, Murayama S, Minegishi N, Suzuki K, Tanno K, Shimizu A, Yamaji T, Iwasaki M, Sawada N, Uemura H, Tanaka K, Naito M, Sasaki M, Wakai K, Tsugane S, Yamamoto M, Yamamoto K, Murakami Y, Nakamura Y, Raychaudhuri S, Inazawa J, Yamauchi T, Kadowaki T, Kubo M, Kamatani Y: Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases. *Nat Genet* 2020, 52:669-79.
- [7] Kakuda N, Yamaguchi H, Akazawa K, Hata S, Suzuki T, Hatsuta H, Murayama S, Funamoto S, Ihara Y: gamma-Secretase Activity Is Associated with Braak Senile Plaque Stages. *Am J Pathol* 2020, 190:1323-31.
- [8] Kameyama M, Ishibashi K, Toyohara J, Wagatsuma K, Umeda-Kameyama Y, Shimoji K, Kanemaru K, Murayama S, Ogawa S, Tokumaru AM, Ishii K: Voxel-based morphometry focusing on medial temporal lobe structures has a limited capability to detect amyloid beta, an Alzheimer's disease pathology. *Ageing (Albany NY)* 2020, 12.
- [9] Kitano T, Sakaguchi M, Yamagami H, Ishikawa T, Ishibashi-Ueda H, Tanaka K, Okazaki S, Sasaki T, Kadono Y, Takagaki M, Nishida T, Nakamura H, Yanase M, Fukushima N, Shiozawa M, Toyoda K, Takahashi JC, Funatsu T, Ryu B, Yoshioka D, Toda K, Murayama S, Kawamata T, Kishima H, Sawa Y, Mochizuki H, Todo K: Mechanical thrombectomy in acute ischemic stroke patients with left ventricular assist device. *J Neurol Sci* 2020, 418:117142.
- [10] Koshi-Mano K, Mano T, Morishima M, Murayama S, Tamaoka A, Tsuji S, Toda T, Iwata A: Neuron-specific analysis of histone modifications with post-mortem brains. *Sci Rep* 2020, 10:3767.
- [11] Moriguchi S, Takahata K, Shimada H, Kubota M, Kitamura S, Kimura Y, Tagai K, Tarumi R, Tabuchi H, Meyer JH, Mimura M, Kawamura K, Zhang MR, Murayama S, Suhara T, Higuchi M: Excess tau PET ligand retention in elderly patients with major depressive disorder. *Mol Psychiatry* 2020.
- [12] Nagano S, Jinno J, Abdelhamid RF, Jin Y, Shibata M, Watanabe S, Hirokawa S, Nishizawa M, Sakimura K, Onodera O, Okada H, Okada T, Saito Y, Takahashi-Fujigasaki J, Murayama S, Wakatsuki S, Mochizuki H, Araki T: TDP-43 transports ribosomal protein mRNA to regulate axonal local translation in neuronal axons. *Acta Neuropathol* 2020, 140:695-713.
- [13] Omura T, Motoyama R, Tamura Y, Nonaka K, Tanei ZI, Shigemoto K, Tokumaru AM, Murayama S, Arai T, Araki A: Meningoencephalitis caused by masked mastoiditis that was diagnosed during a follow-up in an elderly patient with diabetes mellitus: A case report. *Geriatr Gerontol Int* 2020, 20:500-1.
- [14] Schweighauser M, Shi Y, Tarutani A, Kametani F, Murzin AG, Ghetti B, Matsubara T, Tomita T, Ando T, Hasegawa K, Murayama S, Yoshida M, Hasegawa M, Scheres SHW, Goedert M: Structures of alpha-synuclein filaments from multiple system atrophy. *Nature* 2020, 585:464-9.
- [15] Serisawa S, Hirao K, Sato T, Ogawa Y, Kanetaka H, Enomoto M, Shimizu S, Sakurai H, Sakashita Y, Murayama S, Hanyu H: Adult-onset neuronal intranuclear inclusion disease showing markedly high phosphorylated tau protein levels in cerebrospinal fluid. *Geriatr Gerontol Int* 2020, 20:793-5.
- [16] Tanaka H, Homma H, Fujita K, Kondo K, Yamada S, Jin X, Waragai M, Ohtomo G, Iwata A, Tagawa K, Atsuta N, Katsuno M, Tomita N, Furukawa K, Saito Y, Saito T, Ichise A, Shibata S, Arai H, Saïdo T, Sudol M, Muramatsu SI, Okano H, Mufson EJ, Sobue G, Murayama S, Okazawa H: YAP-dependent necrosis occurs in early stages of Alzheimer's disease and regulates mouse model pathology. *Nat Commun* 2020, 11:507.
- [17] Uchino A, Nagai M, Kanazawa N, Ichinoe M, Yanagisawa N, Adachi K, Nanba E, Ishiura H, Mitsui J, Tsuji S, Suzuki K, Murayama S, Nishiyama K: An autopsy case of GM1 gangliosidosis type II in a patient who survived a long duration with artificial respiratory support. *Neuropathology* 2020.
- [18] Yoshinaga S, Yamanaka T, Miyazaki H, Okuzumi A, Hiyaama A, Murayama S, Nukina N: Preserved proteinase K-resistant core after amplification of alpha-synuclein aggregates: Implication to disease-related structural study. *Biochem Biophys Res Commun* 2020, 522:655-61.
- [19] Zhang W, Tarutani A, Newell KL, Murzin AG, Matsubara T, Falcon B, Vidal R, Garringer HJ, Shi Y, Ikeuchi T, Murayama S, Ghetti B, Hasegawa M, Goedert M, Scheres SHW: Novel tau filament fold in corticobasal degeneration. *Nature* 2020, 580:283-7.
- [20] Tanei, S., Saito, Y., ...Murayama, S.: Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases; Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases. *Acta Neuropathol* in press

We published 20 English original peer- reviewed papers in 2020.



**The International Brain Bank Symposium** Post-ICN2018 conference

**DATE** September 28 (Fri.), 2018 13:00-16:30 **VENUE** Tokyo Metropolitan Geriatric Hospital & Institute of Gerontology (Japan)


**Julie A. Schneider** (Rush University Medical Center, USA)  
**Bradley T. Hyman** (Mass. General Hospital, Harvard Medical School, USA)  
**Bernardino Ghetti** (Indiana University, USA)  
**Colin L. Masters** (The University of Melbourne, Australia)  
**Ingeborg Huitinga** (Netherlands Institute for Neuroscience, The Netherlands)  
**Shigeo Murayama** (Tokyo Met. Geriatric Hosp. & Inst. of Gerontology, Japan)

Sponsored by:  
**The Brain Bank for Aging Research**  
 Tokyo Metropolitan Geriatric Hospital & Institute of Gerontology  
 35-2, Sakae-cho, Itabashi, Tokyo, Japan. TEL:+81-3-3964-3241 (Ex.4119)  
 Http://www.mcg.gr.jp/brainbank/index.cgi E-mail:tbres@img.or.jp

Copponsored by:  
 National Center of Neurology and Psychiatry Brain Bank  
 Whana Longitudinal Project of Intractable Neurological Disease and Dementia  
 The Japanese Brain Bank Network for Neuroscience Research  
 Platform for Supporting Cohort Study and Biospecimen Analysis, Grant-in-Aid for Scientific Research on Innovative Areas—Platforms for Advanced Technologies and Research Resources Ministry of Education, Culture, Sports, Science and Technology, Japan  
 Committee on Promoting Collaboration in Life Sciences, Grant-in-Aid for Scientific Research on Innovative Areas—Platforms for Advanced Technologies and Research Resources Ministry of Education, Culture, Sports, Science and Technology, Japan



September 28, 2018  
 @  
 The Brain Bank for Aging Research  
 Tokyo Metropolitan Geriatric Hospital &  
 Institute of Gerontology



In 2018, BBAR organized the international brain bank symposium. Professor Huitinga, the director of Netherland Brain Bank edited Brain Bank Chapter of the Handbook of Clinical Neurology.

## JSNP Brain Bank Committee (1986- )


Chair: Murayama, S. (UO)

- Adachi, T. (Tottori U.)
- Ikeuchi, K. (Genome. Niigata U.)
- Izumi Y. (Neu. Tokushima U)
- Ito, K. (NP. Kyoto Pr. U.)
- Inoue, Y. (Ethis, IMSUT)
- Iritani, S. (Psy. Nagoya U.)
- Oshima, K. (Psy. Matsuzawa H.)
- Kato, T. (Psy, Riken)
- Kaneda, D. (Fukushimura H.)
- Kunii, Y. (Psy. Fukushima)
- Komori, T. (NP. TMNH)
- Kowa, H. (Neu. Kobe U.)
- Saito, Y. (NP. TMGHIG)
- Shimizu, H. (NP. Niigata U.)
- Takao, M. (Lab. NCNP)
- Tanigawa, K. (Pat. Hokkaido U.)
- Taniguchi, D. (Neu. Juntendo U.)
- Tokumaru, A. (Rad. TMGHIG)
- Nishida, N. (For. Toyama U.)
- Nishimura, H. (Pat. Kawasaki U.)
- Hasegawa, M. (Bio. Ch, TMIMR)
- Fujimura, H. (Toneyama H.)
- Furuta T (Pat. Saga U.)
- Matsumoto, H. (For. Osaka U.)
- Beck, G. (Neu. Osaka U.)
- Miki, Y (NP. Hirosaki U.)
- Yamada, M. (NP, Shinshu U.)
- Yokota, O. (Psy, Okayama U.)
- Yoshida, M. (NP, Aichi M. U.)

The JSNP (Japanese Society of Neuropathology) Brain Bank Committee supports JBBN and JBBNNR for quality assurance of neuropathological diagnosis. The committee covers all areas of Japan.


## The philosophical background

- The respect for general autopsy since Edo era for evidence- based medicine.
- The Brain Bank Committee, the Japanese Society of Neuropathology supports quality assurance of brain banking in neuropathological diagnosis, legal regulation and COI.
- Japanese tradition, “Okagesan”.




The philosophical background of brain bank is deep respect for autopsy. The brain bank committee supports brain banking for more than twenty years. Japanese tradition, “Okagesan” is based on this activity.





The BBAR follows the framework of Alzheimer Disease Research Coordinating Center in US.



Our brain bank project includes biobanking of CSF, plasma and genome of living patients and controls.

## BBAR Resource Center

- A full time coordinator.
- All BBAR records stored in our digital clinical chart system with Brain Bank ID.
- BBAR Resource Center: 24 deep freezers, including one for a national prion back- up bank
- >7000 case paraffin blocks
- BBAR Data Center: a virtual slide system for educational output.
- BBAR Internet Conference Room with NCNP, Osaka U., Toneyama and Fukushima




The Brain Bank for Aging Research (BBAR) employs a full-time coordinators. All BBAR registrants' data are stored in clinical chart system with the brain bank ID. We have a resource center, carrying 24 deep freezers and paraffin blocks of more than 7000 cases.


The BBAR Data Center is equipped with a virtual slide system for neuropathological education. The BBAR network conference room is connected to the National Center for Neurology and Psychiatry (NCNP), Osaka University, NHO Osaka Toneyama Medical Center and Fukushima Brain Bank for neuropathology quality assurance conference once a week.

## Autopsy of Brains

- Each case is handled by an attending brain bank doctor (neuropathologist) and a technician (specially trained), in collaboration with an attending general pathologist and two technicians.
- The attending brain bank doctor determines the frozen side.
- The doctor forms 8mm-thick serial coronal slices of the brain, 5mm-thick serial sagittal slices of the cerebellum and 5mm-thick axial slices of the brain stem.
- The technician takes photos and freezes tissues immediately.



In our brain bank system, each autopsy is conducted by a general pathologist, an autopsy technician and a laboratory technician, in collaboration with a neuropathologist and a brain bank technician (2). Thus, every autopsy is handled by at least five professionals.






Spinal cords are recovered from all cases. After sampling for histopathological evaluations, the remaining spinal cords are frozen for biochemical and molecular studies.

## Total RNA Quality Check (Dpt. Mol. Biol. Niigata Univ. BRI)

### DNA & RNA Back Up

BBAR (N=48: ROW) vs Control (N=78: NP)

RNA Quality of BBAR is better than rapid autopsy control, probably **due to a very short cooling interval (interval between death and transfer to a refrigerator)**.



080121 (Mon)


In collaboration with the Department of Molecular Biology, the Brain Research Institute at Niigata University (BRIN), we check the RNA qualities of all cases to meet NIH requirement. Niigata works as DNA/ RNA backup bank.

## BBAR Resource (Frozen)

- Half brain after sampling small pieces of tissues for weak fixation.
- Entire spinal cord, after sampling the segments for pathological evaluation.
- Peripheral autonomic nervous system: sympathetic ganglia, esophago- columnar junction, heart, skin and olfactory plate.
- Skeletal muscle: biceps brachii (for the study of sarcopenia)
- General organs: small pieces of liver, kidney, lung, esophagus
- Serum (stored in the hospital laboratory).

Frozen resource includes half brain, entire spinal cord, peripheral autonomic nervous system, skeletal muscle, small pieces of general organs and serum.

# BBAR Protocol ([www.mci.gr.jp](http://www.mci.gr.jp))



8 areas: 4% paraformaldehyde over 2 nights  
(McGeer's method @ British Columbia)

From the frozen side, eight small samples from specific anatomical areas are fixed in 4% paraformaldehyde over two nights for better correlation with studies of experimental animals.



## Brain Cutting (1972.5.1-)




In collaboration of Neurology, Neuropathology, Psychiatry, Pathology and Rehabilitation, connected via internet.

Brain Cutting is an important activity for diagnosis and education, connected with BBAR, NCNP, Osaka University and Toneyama Medical Center.

# BBAR Protocol: Fixed Side

Brain: 29 areas; Spinal Cord: 9 segments



Tissue blocks were obtained from a fixed side, in compliance with CERAD requirements, DLB Consensus Guideline, and Braak's recommendation that requires evaluation of bilateral amygdala and hippocampi.

## BBAR Protocol: Histological Examination.



Internationally Standardized  
Neuropathological Diagnostic Method



Paraffin block of >7,000 cases  
easily accessible



Library

We have been accumulating glass slides and paraffin blocks in the BBAR Resource Center.

## BBAR Resource (Fixed)

- 4% paraformaldehyde over two nights, one half for paraffin embedding and another half preserved in 20% sucrose PBS+0.1% NaN<sub>3</sub>
- Brain: frontal, temporal and occipital poles, intraparietal sulcus, anterior amygdala, posterior hippocampus, midbrain, dentate nucleus, olfactory bulb
- Spinal Cord: C4/8, T4/8/12, L5, S2
- Peripheral ANS: sympathetic ganglia, esophago-columnar junction, anterior wall of the left ventricle of the heart, skin, olfactory plate, biceps brachii
- 20% buffered formalin for 7-13 days
- Half brain, body organs

Fixed tissue resource consists of paraform- fixed tissues from a frozen half and buffered- formalin fixed tissues from a fixed half of the brain

## Staining


Routine : H.E., K.B.

Special : Gallyas-Braak, methenamine silver,  
Elastica Masson, Congo red, thioflavin S

Immunohistochemistry with automatic stainer (Ventana)

Epitope	Antibody	Clone
A $\beta$ 11-28aa	12B2 (IBL)	monoclonal
phosphorylated tau	AT8 (Fujirebio)	monoclonal
3R/ 4R tau	RD3/ RD4	monoclonal
phosphorylated $\alpha$ - synuclein	psyn64 (Wako)	monoclonal
Ubiquitin	Sigma	polyclonal
Phosphorylated TDP43	PSer409/410	monoclonal
FUS/ TLS	Sigma	polyclonal

Immunohistochemical screenings of all autopsy cases are performed with commercially available antibodies.



A section of hippocampus fixed in 4% paraformaldehyde presented numerous A-beta (11-28)- immune- positive deposits in the parenchyma and the walls of vessels.

P & CNS Screening		tau										Lewy TDP										Aβ									
		PT	NFT	GT	NT	NP	AG		AT		Psyn		TDP-43		DP		CP		A/V		CAA										
Y-977		R	L	RSA	BLA	R	L	R	L	R	L	R	L	R	L	R	L	R	L	R	L										
Sympathetic ganglion																															
Dorsal root ganglion																															
Spinal cord																															
Sacral anterior horn																															
Sacral posterior horn																															
Intermediate zone (Sacral)																															
Lumbar anterior horn																															
Lumbar posterior horn																															
Lumbar anterior column																															
Lumbar lateral column																															
Lumbar posterior column																															
Thoracic anterior horn																															
Thoracic posterior horn																															
Intermediolateral N. (Thoracic)																															
Cervical anterior horn																															
Cervical posterior horn																															
Medulla oblongata																															
Dorsal motor N. of vagus																															
Hypoglossal N.																															
Inferior olivary N.																															
Pons																															
Pontine N.																															
Locus ceruleus																															
Subpretectum																															
Pedunculopontine N.																															
Midbrain																															
Oculomotor N.																															
Edinger-Westphal N.																															
Pars compacta of SN																															
Periaqueductal gray matter																															
Cerebellum																															
Cerebellar cortex																															
Cerebellar white matter																															
Dentate N.																															
Interbrain / Basal ganglia																															
Broca's diagonal band																															
Hypothalamus																															
Nucleus basalis of Meynert																															
Accumbens N.																															
Caudate N.																															
Putamen																															
Ext. globus pallidus																															
Int. globus pallidus																															
Claustrum																															
Subthalamic N.																															
Thalamus																															
Allocortex (Rhinecephalon/Limbic)																															
Olfactory bulb periphery																															
Anterior olfactory N.																															
Piriform cortex (frontal)																															
Piriform cortex (temporal)																															
Amygdala																															
Locus / Ambient gyrus																															
Dentate gyrus																															
Hippocampus CA4																															
Hippocampus CA3																															
Hippocampus CA2																															
Hippocampus CA1																															
Subiculum																															
Presubiculum																															
Entorhinal																															
Transentorhinal																															
Insular cortex																															
Anterior cingulate gyrus																															
Temporal pole (medial)																															
Cerebral neocortex (isocortex)																															
T4																															
T2																															
Fronal pole																															
F2																															
Supramarginal gyrus																															
Visual association cortex																															
Crate area																															
Primary motor cortex																															

We screen all cases immunohistochemically. Blue highlights denote the peripheral autonomic nervous system, and the orange rectangle, the spinal cord.

## BBAR Degenerative Pathology Database


BBAR	Y96XX									
A/G	CDR	PMI	NFT	AT8	SP	CERAD	Thal	LB	LB score	DLB 3rd
93M	3	11:22	4/3	3/3	2	2	5	4	4	Limbic (amygdala predominant)
Grain	AA	AT	UD	TDP	ApoE	RIN				NPD
0.5/ 0.5	1C	1	3	T1M1S0	3/3	8.1				AD, LBD, CVDE


A/G age/ gender  
 CDR (clinical dementia rating): 0-3  
 PMI: postmortem interval  
 NFT (tangle: Braak Stage): 0-6  
 AT8 (tangle: AT8 Stage): 0-6  
 SP (senile plaque: Braak Stage): 0-3  
 CERAD: 0-3 (0- C)  
 Thal (amyloid Thal Stage): 0-5  
 Lewy (Lewy body, BBAR Stage): 0-5  
 DLB score (DLB 1<sup>st</sup> Consensus Guideline)  
 DLB 3<sup>rd</sup> (DLB 3<sup>rd</sup> Consensus Guideline)  
 Grain (argyrophilic grain, Saito Stage): 0-3  
 AA (amyloid angiopathy, BBAR Stage): 0-3  
 AT (astrocytic tangle): 0-3  
 UD (ubiquitinated dots): 0-3  
 TDP (TDP-43 proteinopathy, temporal, medulla and spinal): 0-3  
 ApoE (apoE genotyping)  
 RIN (RNA integrity number)  
 NPD: neuropathologic diagnosis (AD: Alzheimer disease; LBD: Lewy body disease; CVDE: embolic infarct)

Each case is evaluated with international standards. Researchers who apply to BBAR choose samples based on this database.



Braak NFT/ SP **DNA Resource (1,890 cases)**




	0	I	II	III	IV	V	VI	計
 0	34 66.3	314 75.8	102 81.8	46 85.6	12 85.4	1 81.0	0	509 77.5
A	16 75.5	350 78.0	149 83.6	74 86.2	23 88.6	1 99.0	0	613 80.6
B	8 76.1	169 79.9	91 82.8	70 85.6	23 91.2	2 82.0	1 94.0	364 82.4
C	3 76.0	50 79.4	51 83.0	80 84.5	80 86.6	100 86.4	40 83.9	404 84.4
計	61 70.5	883 77.7	393 82.9	270 85.4	138 87.6	104 86.4	41 84.1	1890 80.9

Case #  
Average Age

Alzheimer Disease: 220/ 1890 = 11.6%

DNA resources represent progressive accumulation of tangles and plaques. We adopt Braak NFT Stage equal to or more than IV and SP Stage C for diagnosis of Alzheimer disease.



In our most recent 205 consecutive autopsy cases, 36% contained Lewy body pathology. We published the results in Acta Neuropathologica in 2020.



Higashihara M.

54 ALS/ MND Brain and Spinal Cord Resource (300 frozen control spinal cord) in 506 JaCALS registrants  
Westmead detecting upper motor neuron sign for early diagnosis of ALS


Matsubara, T.

ALS/MND Sym @Perth 2019

Index		Clinical data			Diagnosis of first visit		Neuroimaging/Depression				TOP-4 pathology										Other pathological data												
No.	Clinical Diagnosis (Last visit)	Clinical Diagnosis (First visit)	Age at Death	Sex	Site of Onset	Duration from onset to diagnosis (month)	Duration from onset to PPV (month)	Duration from onset to death (month)	Upheld (w/)	rESC	PMC	normal tract	SC	BS	Nucleus Basalis	PMC	SC	ID	FF	FN	FF	Stem	DG	Hg	EC	BrainSP Stage	BrainH1 Stage	Solo A20-PPV Stage	Brain Age (yr)				
1	PLM	PLM	65	M	U	0	5	-	36	Not Applicable	1	2	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1153
2	PLM	PLM	76	M	U	0	7	-	65	Not Applicable	1	1	2	2	1	1	4	5	2	4	1	0	0	0	0	0	0	0	1	0	0	1420	
3	PLM	PLM	74	F	L	0	60	-	108	Not Applicable	1	2	2	2	1	1	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1103	
4	PLM	ALS-possible	84	M	U	0	5	-	37	Not Applicable	1	1	2	2	0	1	2	3	4	1	2	NA	0	0	0	0	0	1	2	0	1	1863	
5	PLM	ALS	70	M	U	1	10	-	35	Not Applicable	1	2	2	2	4	2B	4	5	5	4	4	5	5	5	2	6	0	1	0	0	1333		
6	ALS-possible	ALS-possible	68	M	T, U	0	3	-	9	Possible	1	2	1	2	2	1	0	4	5	2	4	2	0	1	0	0	0	0	1	0	0	1410	
7	ALS-possible	ALS-possible	62	M	B	0	16	-	25	Possible	1	2	3	2	4	2A	0	3	4	1	4	4	4	0	2	5	1	2	1	0	1389		
8	ALS-possible	ALS-possible	64	M	B	0	9	-	30	Possible	1	3	2	3	1	1	3	3	2	4	2	NA	3	0	0	0	0	1	1	0	1426		
9	ALS-possible + PD	ALS + PD	80	F	U	0	7	-	39	Possible	3	3	3	3	3	1	6	1	4	3	3	3	0	0	0	0	0	1	0	0	1356		
10	ALS-possible (LM tag predominant)	ALS	61	F	B	0	7	-	38	Possible	2	2	3	2	4	2A	6	3	5	2	5	5	3	2	2	3	1	1	0	2	1421		
11	ALS-possible (LM tag predominant)	ALS	81	M	B	0	15	-	48	Possible	2	2	2	2	2	1	5	4	4	2	5	3	0	2	0	0	0	1	2	0	1392		
12	ALS-possible (leukotary supported)	ALS	68	M	U	0	11	-	14	Probable (leukotary supported)	1	2	3	2	3	1	5	5	5	1	5	3	0	3	0	0	0	1	2	0	1253		
13	ALS-possible (leukotary supported)	ALS	78	M	L	0	12	-	16	Probable (leukotary supported)	1	2	2	2	2	1	3	5	5	1	5	0	0	NA	0	0	0	0	1	0	0	1360	
14	ALS-possible (leukotary supported)	ALS	59	M	L	0	10	-	65	Probable (leukotary supported)	1	3	2	3	4	2B	5	6	5	6	6	5	NA	6	5	5	5	1	1	0	1343		
15	ALS-possible + PSP	ALS + PSP	61	M	U	1	1	-	5	Possible	1	1	2	2	4	2A	0	4	5	2	3	2	NA	6	5	5	5	0	1	0	1243		
16	ALS-possible	ALS	76	M	B	0	6	-	7	Possible	2	2	1	1	4	2A	5	4	4	2	4	2	NA	3	5	4	5	1	2	1	1448		
17	ALS-possible	ALS	60	F	B	1	2	-	10	Possible	2	3	1	2	4	2B	6	3	6	2	2	5	6	3	6	3	6	0	1	0	1388		
18	ALS-possible + PD	ALS + PD	68	M	U	0	6	-	13	Possible	2	2	2	2	0	1	3	5	4	2	3	0	0	0	0	0	0	1	1	0	1370		
19	ALS-possible	ALS	62	M	U	1	14	-	14	Possible	2	3	3	2	4	2B	5	2	5	4	3	4	5	3	5	2	3	0	1	0	1253		
20	ALS-possible	ALS	67	M	L	0	4	-	14	Possible	2	3	2	2	3	1	5	5	4	2	3	1	0	3	0	0	0	2	1	0	1373		
21	ALS-possible	ALS	72	F	L	0	7	-	15	Possible	2	3	3	3	4	2A	6	5	5	3	5	4	3	5	5	3	5	1	1	0	1370		
22	ALS-possible + PD	ALS + PD	60	F	U	0	4	-	17	Possible	3	3	2	2	4	2A	6	5	6	3	5	2	4	6	3	5	1	1	2	0	1386		
23	ALS-possible	ALS	70	F	L	0	4	-	20	Possible	2	3	3	3	3	1	5	5	4	5	4	2	3	0	0	0	1	1	0	1	1241		
24	ALS-possible	ALS	65	F	B	1	4	-	37	Possible	2	3	3	3	4	1	5	4	5	5	5	2	4	0	0	2	0	0	0	0	0	1451	
25	ALS-possible	ALS	60	M	U	1	10	-	60	Possible	1	2	2	3	4	2A	0	3	5	2	3	2	5	6	5	3	6	0	1	1	1	1330	
26	ALS-definite	ALS	73	M	L	1	7	-	8	Definite	1	2	3	1	4	2A	0	1	5	2	3	0	2	3	2	2	4	1	1	0	0	1110	
27	ALS-definite	ALS	63	M	U	0	7	-	9	Definite	2	3	2	3	2	1	5	6	5	3	3	0	NA	0	0	0	0	0	1	1	0	1488	
28	ALS-definite	ALS	71	F	B	1	9	-	12	Definite	1	2	3	2	4	2A	5	5	5	3	4	5	2	5	4	3	3	0	2	2	0	1379	
29	ALS-definite	ALS	69	F	B	1	10	-	13	Definite	1	3	3	2	4	2B	6	3	5	3	4	5	4	6	4	5	3	1	3	0	1386		
30	ALS-definite	ALS	80	F	B	1	10	-	17	Definite	2	3	3	3	3	1	5	2	5	2	2	2	0	3	0	0	0	1	3	0	1391		
31	ALS-definite	ALS	63	M	U	0	9	-	21	Definite	2	3	3	3	4	2A	5	5	5	3	5	5	3	2	3	5	0	1	0	0	1381		
32	ALS-definite	ALS	75	M	B	0	7	-	22	Definite	2	2	3	3	4	2A	4	3	4	3	4	5	5	3	4	2	4	0	0	0	1	1453	
33	ALS-definite	ALS	45	M	U	0	240	-	264	Definite	3	3	3	3	1	1	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	1471	
34	ALS-possible	ALS with TPPV	61	F	B	0	8	43	76	Possible	2	3	3	3	4	2A	4	2	4	2	3	2	0	3	2	0	2	0	1	0	0	1383	
35	ALS-possible	ALS with TPPV	71	M	U	0	56	66	146	Possible	3	3	3	3	3	1	4	1	3	3	3	1	0	3	0	0	0	1	1	0	1320		
36	ALS-possible (leukotary supported)	ALS with TPPV	63	M	L	0	15	15	36	Probable (leukotary supported)	2	3	3	3	4	2A	6	0	5	3	2	5	5	NA	4	3	3	1	1	0	0	1429	
37	ALS-possible (leukotary supported)	ALS with TPPV	60	M	U	0	7	14	102	Probable (leukotary supported)	3	3	3	3	4	2A	2	1	1	1	3	2	5	6	1	4	5	0	1	0	0	792	
38	ALS-possible	ALS with TPPV	70	M	B	0	49	70	103	Possible	2	3	3	3	3	1	5	1	3	3	3	3	3	3	3	0	0	0	0	0	0	0	1056
39	ALS-possible	ALS with TPPV	67	M	U	0	17	53	147	Possible	3	3	3	3	4	2A	4	1	3	3	3	2	2	4	3	2	4	1	1	0	2	1291	
40	ALS-possible	ALS with TPPV	69	M	U	0	62	90	113	Possible	3	3	3	3	2	1	3	1	5	3	3	2	1	1	0	0	0	0	0	0	0	1610	
41	ALS-possible	ALS with TPPV	74	M	B	1	25	39	75	Possible	3	3	3	3	4	2A	4	2	4	4	5	3	3	4	2	2	4	1	1	0	0	1210	
42	ALS-definite	ALS with TPPV	63	M	B	0	10	20	29	Definite	3	3	3	3	1	3	5	3	5	3	4	5	0	3	0	0	0	0	0	0	0	1246	
43	ALS-definite	ALS with TPPV	69	M	R	0	10	47	55	Definite	1	2	3	3	3	1	4	2	4	1	3	3	0	3	0	0	0	0	0	0	0	0	1069
44	TLS	ALS	45	M	L	0	42	-	100	Possible	3	3	2	3	3	1	6	1	3	3	4	1	0	2	0	0	0	0	0	0	0	0	1251
45	ALS with aggregates of corpus callosum	ALS with TPPV	68	M	B	0	9	-	39	Possible	1	1	3	2	3	1	3	4	3	3	3	5	3	3	0	0	0	0	0	0	0	0	1411
46	ALS?	ALS with TPPV	80	M	L	1	13	19	46	Not Applicable	2	2	2	2	1	1	5	5	5	1	3	3	0	0	0	0	0	0	4	2	3	0	1391
47	ALS?	ALS	77	M	L	0	6	-	78	Not Applicable	1	1	2	2	1	1	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1341	

We establish ALS bank in collaboration with Tokushima University together with 300 control spinal cord.

The first autopsy case of JADNI participant from Tohoku University, just after the Great East Japan Earthquake



I will go anywhere when there is a will of brain donation

I recovered the first JADNI participant autopsy from Tohoku University. The autopsy was done just after the Higashinippon Earthquake, and I went to Tohoku University to recover this brain.

## CJD Surveillance Committee Pathology Core

- To promote autopsies of prion disease.
- To receive autopsies of outside cases.
- To report to the committee on autopsy- proven prion cases (pathology route)
- Quality control of pathological findings of registered cases.
- To establish a national prion back- up bank.
- To study natural course of prion disease.

Grants in Aid from Ministry of Health, Labor and Welfare, Japan

I am a pathology core of the Japanese CJD Surveillance Committee and contribute to prion research.

## International Collaboration

- Collaboration with Sydney Parkinson Disease Brain Bank funded by Michael J Fox Foundation (Prof. Halliday).
- Collaboration with Sydeney Westmead Hospital for ALS research
- Collaboration with Cambridge for atomic force microscope

We promote international collaboration.

## Brain Bank and Bioresource Center, Osaka University (2021)

### Brain Bank for Neurodevelopmental, Neurological and Psychiatric Disorder

Chair (Prof.)	Murayama, S.	Concurrent	Prof. Mochizuki, H. (Neurology)
Concurrent (Neuro)	Assi. P. Beck, G.		Prof. Taniike, M. (Child Develop.)
M.D. Ph.D. Course	Yonenobu, Y.		Prof. Ikeda M. (Psychiatry)
	Yamashita, R.		Prof. Matsumoto, H. (Legal Med.)

## BBAR Project (2021)

### Brain Bank for Aging Research (BBAR)

Chair	Saito, Y.
<i>Pathology Core</i>	<i>Murayama, S.</i>
Clinical Core	Iwata, A.
Staff	Matsubara, H.
Fellow	Arakawa, A.
Resident	Orita, M.
<i>Visiting Scholar</i>	<i>Uchino, A.</i>
	<i>Shioya A</i>
Research Manager	<i>Morishima, M.</i>
Coordinator	Obata, M.

### Neuropathology

Chair	Saito, Y.
Staff (cross appoint)	Murayama, S.

### PET Center

Chair	Ishii, K.
-------	-----------

### Neurology

Chair:	Iwata, A.
Co- Chair:	Kanemaru, K.
Vice- Chair,	Nishina, N.
	Higashihara, M.
	Ihara, R.
Staff:	Hatano, A.
	Kuriyama,
<i>Res. Resident:</i>	<i>Morimoto, S.</i>

### Rehabilitation

Senior:	Kato, T.
---------	----------

### Psychiatry

Chair:	Furuta, K.
--------	------------

### Pathology

Chair	Arai, T.
-------	----------

### Radiology

Chair	Tokumaru, A.
-------	--------------

The list of BBNNPD and BBAR members.